Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Terminated 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Lymphoma 17Lymphoma, Large B-Cell, Diffuse 12Lymphoma, Non-Hodgkin 8Lymphoma, Follicular 8Lymphoma, Large-Cell, Immunoblastic 6Lymphoma, T-Cell, Peripheral 4Lymphoma, Large-Cell, Anaplastic 4Lymphoma, Mantle-Cell 3Burkitt Lymphoma 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia 2Immunoblastic Lymphadenopathy 2Waldenstrom Macroglobulinemia 1Sezary Syndrome 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Mycosis Fungoides 1Lymphoma, B-Cell 1Lymphoma, AIDS-Related 1HIV Infections 1Cardiotoxicity 1

Interventions

Peripheral Blood Stem Cell Transplantation 38fludarabine phosphate 36Cyclophosphamide 31Mycophenolic Acid 28Cyclosporine 25Whole-Body Irradiation 24Tacrolimus 22Busulfan 18Antilymphocyte Serum 18Radiotherapy 16Methotrexate 16Filgrastim 14Etoposide 13Methylprednisolone 10Lenalidomide 10Bortezomib 10Vorinostat 9Melphalan 9Flow Cytometry 9Rituximab 8Gemcitabine 8Cord Blood Stem Cell Transplantation 7Bexarotene 7pembrolizumab 6mogamulizumab 6Alemtuzumab 6tanespimycin 5fludarabine 5aldesleukin 5Transplantation 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Sezary Syndrome × VAP-cyclo protocol × Clear all
NCT00060385 2012-09-24

Combination Chemotherapy With or Without Etoposide in Treating Older Patients With Non-Hodgkin's Lymphoma

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2/3 Terminated
3 enrolled
DermatologicLymphoidOther hematologic neoplasm

Lymphoma, Mycosis Fungoides, Sezary Syndrome, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡